PARP inhibitor biomarkers are used for tissue analysis and molecular profiling to identify homologous recombination deficiency (HRD) positive cancers. These biomarkers help doctors determine a patient's sensitivity to PARP inhibitor drugs. They play a vital role in cancer treatment and targeted therapy selection. The detection of HRD positive cancers allows more effective PARP inhibitor therapies to be designed for patients. The global PARP inhibitor biomarkers market is estimated to be ... Read more

Cancer treatments have advanced significantly in the past few decades. Targeted therapies have improved outcomes for many patients by going after specific vulnerabilities in tumor cells. One promising class of targeted drugs known as PARP inhibitors is showing great promise, particularly for cancers with defects in the BRCA genes. However, to maximize the benefits of these therapies, identifying useful biomarkers is crucial.

What are PARP Inhibitors?
PARP (poly ... Read more